The Journal of Clinical Psychopharmacology has published a post hoc analysis of data from the Phase III KINECT-4 study of Ingrezza (valbenazine).
Developed by Neurocrine Biosciences (Nasdaq: NBIX), Ingrezza is the only once-daily selective VMAT2 inhibitor approved for people with tardive dyskinesia and the treatment of chorea associated with Huntington's disease.
The new analysis looks at long-term real-world outcomes, and showed that nearly all study participants met the threshold for clinically meaningful improvements.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze